Salma Machan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Salma Machan has a total of 220 co-authors. Here are the top co-authors by number of shared publications:
Luis Requena
Department of Dermatology, Fundación Jiménez Díaz, Universidad Autonoma de Madrid, Madrid, Spain
14 shared publicationsRaúl Córdoba
Haematology Department Hospital Universitario Fundación Jiménez Díaz, Universidad Autónoma Madrid Spain
6 shared publicationsDiana Camacho
Department of Dermatology, Hospital Universitario Fundacion Jiménez Diaz, Universidad Autónoma, Madrid, Spain
5 shared publications- Miguel Angel Piris
Pathology
5 shared publications Úrsula Pielasinski
Department of Dermatology, Fundación Jiménez Díaz Universidad Autónoma Madrid Spain
5 shared publications- Luis Requena
Department of Dermatology Hospital Universitario Fundación Jiménez Díaz Madrid Spain
4 shared publications
Latest Publications
- 20 May 2024
- Published by Wiley in Journal of Cutaneous Pathology
- Vol. 51 (9) , 649-653
Urticarial mycosis fungoides: A distinctive presentation with blood involvement and a peculiar immunophenotype
Mycosis fungoides (MF) has been widely reported to mimick a considerable number of different dermatoses, including scarring alopecia, bullous dermatoses or cysts, and comedones. In atypical presentations, histopathology is essential for the diagnosis. We present two cases of MF with clinical urticarial lesions and a striking blood involvement that responded to mogamulizumab treatment. Histopathologically, both cases had classic MF features and shared a peculiar immunophenotype, with positivity for CD25 and FOXP3. Differential diagnoses included urticarial lymphomatoid drug reactions and other lymphomas, like T‐cell prolymphocytic leukemia, atypical Sézary syndrome, or adult T‐cell lymphocytic leukemia. A low suspicion threshold is necessary for the diagnosis of atypical presentations of MF.
- 20 May 2024
- Published by Wiley in Journal of Cutaneous Pathology
- Vol. 51 (9) , 649-653
Urticarial mycosis fungoides: A distinctive presentation with blood involvement and a peculiar immunophenotype
Mycosis fungoides (MF) has been widely reported to mimick a considerable number of different dermatoses, including scarring alopecia, bullous dermatoses or cysts, and comedones. In atypical presentations, histopathology is essential for the diagnosis. We present two cases of MF with clinical urticarial lesions and a striking blood involvement that responded to mogamulizumab treatment. Histopathologically, both cases had classic MF features and shared a peculiar immunophenotype, with positivity for CD25 and FOXP3. Differential diagnoses included urticarial lymphomatoid drug reactions and other lymphomas, like T‐cell prolymphocytic leukemia, atypical Sézary syndrome, or adult T‐cell lymphocytic leukemia. A low suspicion threshold is necessary for the diagnosis of atypical presentations of MF.
- Open Access
- 2 December 2023
- Published by Elsevier in Actas Dermo-Sifiliograficas
- Vol. 115 (2) , T119-T129
[Translated article] Cost of Treating Cutaneous T-Cell Lymphoma in Spain: Analysis of MICADOS Study Data by Disease Stage
- 2 December 2023
- Published by Elsevier in Actas Dermo-Sifiliograficas
- Vol. 115 (2) , T119-T129
Open Access[Translated article] Cost of Treating Cutaneous T-Cell Lymphoma in Spain: Analysis of MICADOS Study Data by Disease Stage
- Open Access
- 9 September 2023
- Published by Elsevier in Actas Dermo-Sifiliograficas
- Vol. 115 (2) , 119-129
Evaluación de los costes asociados a la enfermedad de pacientes con linfoma cutáneo de células T en España: análisis en función del estadio clínico (estudio MICADOS)
- 9 September 2023
- Published by Elsevier in Actas Dermo-Sifiliograficas
- Vol. 115 (2) , 119-129
Open AccessEvaluación de los costes asociados a la enfermedad de pacientes con linfoma cutáneo de células T en España: análisis en función del estadio clínico (estudio MICADOS)
- 9 September 2022
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 37 (1) , 57-64
Brentuximab vedotin in the treatment of cutaneous T‐cell lymphomas: Data from the Spanish Primary Cutaneous Lymphoma Registry
ABSTRCT: Background: Brentuximab vedotin (BV) has been approved for CD30‐expressing cutaneous T‐cell lymphoma (CTCL) after at least one previous systemic treatment. However, real clinical practice is still limited.Objectives: To evaluate the response and tolerance of BV in a cohort of patients with CTCL.Methods: We analysed CTCL patients treated with BV from the Spanish Primary Cutaneous Lymphoma Registry (RELCP).Results: Sixty‐seven patients were included. There were 26 females and the mean age at diagnosis was 59 years. Forty‐eight were mycosis fungoides (MF), 7 Sézary syndrome (SS) and 12 CD30+ lymphoproliferative disorders (CD30 LPD). Mean follow‐up was 18 months. Thirty patients (45%) showed at least 10% of CD30+ cells among the total lymphocytic infiltrate. The median number of BV infusions received was 7. The overall response rate (ORR) was 67% (63% in MF, 71% in SS and 84% in CD30 LPD). Ten of 14 patients with folliculotropic MF (FMF) achieved complete or partial response (ORR 71%). The median time to response was 2.8 months. During follow‐up, 36 cases (54%) experienced cutaneous relapse or progression. The median progression free survival (PFS) was 10.3 months. The most frequent adverse event was peripheral neuropathy (PN) (57%), in most patients (85%), grades 1 or 2.Conclusions: These results confirm the efficacy and safety of BV in patients with advanced‐stage MF, and CD30 LPD. In addition, patients with FMF and SS also showed a favourable response. Our data suggest that BV retreatment is effective in a proportion of cases.
- 9 September 2022
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 37 (1) , 57-64
Brentuximab vedotin in the treatment of cutaneous T‐cell lymphomas: Data from the Spanish Primary Cutaneous Lymphoma Registry
ABSTRCT: Background: Brentuximab vedotin (BV) has been approved for CD30‐expressing cutaneous T‐cell lymphoma (CTCL) after at least one previous systemic treatment. However, real clinical practice is still limited.Objectives: To evaluate the response and tolerance of BV in a cohort of patients with CTCL.Methods: We analysed CTCL patients treated with BV from the Spanish Primary Cutaneous Lymphoma Registry (RELCP).Results: Sixty‐seven patients were included. There were 26 females and the mean age at diagnosis was 59 years. Forty‐eight were mycosis fungoides (MF), 7 Sézary syndrome (SS) and 12 CD30+ lymphoproliferative disorders (CD30 LPD). Mean follow‐up was 18 months. Thirty patients (45%) showed at least 10% of CD30+ cells among the total lymphocytic infiltrate. The median number of BV infusions received was 7. The overall response rate (ORR) was 67% (63% in MF, 71% in SS and 84% in CD30 LPD). Ten of 14 patients with folliculotropic MF (FMF) achieved complete or partial response (ORR 71%). The median time to response was 2.8 months. During follow‐up, 36 cases (54%) experienced cutaneous relapse or progression. The median progression free survival (PFS) was 10.3 months. The most frequent adverse event was peripheral neuropathy (PN) (57%), in most patients (85%), grades 1 or 2.Conclusions: These results confirm the efficacy and safety of BV in patients with advanced‐stage MF, and CD30 LPD. In addition, patients with FMF and SS also showed a favourable response. Our data suggest that BV retreatment is effective in a proportion of cases.
- Open Access
- 7 July 2022
- Published by Wiley in JEADV Clinical Practice
- Vol. 1 (4) , 438-449
EORTC‐QLQ‐C30 and SKINDEX‐29 measurement of health‐related quality of life in patients with mycosis fungoides and Sézary syndrome: Real‐world data in Spanish patients (MICADOS Study)
Background: Few studies have explored the impact of cutaneous T‐cell lymphoma (CTCL) on health‐related quality of life (HRQoL) and compared it to other patients with cancer.Objectives: The primary objective of the study was to assess the QoL of patients diagnosed with the mycosis fungoides (MF) and Sézary syndrome (SS) types of CTCL in Spain.Methods: A cross‐sectional observational study was completed recruiting adult patients with MF and SS, exploring the European Organisation for Research and Treatment of Cancer‐Core Quality of Life Questionnaire, version 3 (EORTC‐QLQ‐C30v3) and Skindex‐29 HRQoL and itching intensity.Results: A total of 141 patients [81 males (57.4%) and mean age of 63.6 years (95% CI: 61.4–65.7)], were included. EORTC‐QLQ‐C30 global health status showed worse scores in CTCL patients compared to healthy population (p < 0.05) and did not differ from other patients with cancer. The physical and role functioning of CTCL patients were better than other patients with cancer (p < 0.05) but worse than healthy population (p < 0.05). The social functioning was similar to other patients with cancer but worse than healthy (p < 0.05). In the global health status, better scores were observed with aging (p = 0.023) and worse scores in patients with Eastern Cooperative Oncology Group (ECOG)‐1 versus ECOG‐0 (p = 0.01). The Skindex‐29 global score was 28.5 (95% CI: 24.8–32.3), being worst at higher clinical stage (p < 0.05) and at higher pruritus intensity (p < 0.001) and better for older patients (p < 0.001). More itching was related to female sex (p = 0.016), younger patients (p = 0.035), higher ECOG (p < 0.05) and higher m‐SWAT scores (p = 0.006).Conclusions: These results allow mapping HRQoL affectation in CTCL patients. Global health status in MF/SS was like other patients with cancer and worse than the age‐matched healthy population. The highest impact in Skindex‐29 and EORTC‐QLQ‐C30 was associated with young age, ECOG, pruritus and disease stage.
- 7 July 2022
- Published by Wiley in JEADV Clinical Practice
- Vol. 1 (4) , 438-449
Open AccessEORTC‐QLQ‐C30 and SKINDEX‐29 measurement of health‐related quality of life in patients with mycosis fungoides and Sézary syndrome: Real‐world data in Spanish patients (MICADOS Study)
Background: Few studies have explored the impact of cutaneous T‐cell lymphoma (CTCL) on health‐related quality of life (HRQoL) and compared it to other patients with cancer.Objectives: The primary objective of the study was to assess the QoL of patients diagnosed with the mycosis fungoides (MF) and Sézary syndrome (SS) types of CTCL in Spain.Methods: A cross‐sectional observational study was completed recruiting adult patients with MF and SS, exploring the European Organisation for Research and Treatment of Cancer‐Core Quality of Life Questionnaire, version 3 (EORTC‐QLQ‐C30v3) and Skindex‐29 HRQoL and itching intensity.Results: A total of 141 patients [81 males (57.4%) and mean age of 63.6 years (95% CI: 61.4–65.7)], were included. EORTC‐QLQ‐C30 global health status showed worse scores in CTCL patients compared to healthy population (p < 0.05) and did not differ from other patients with cancer. The physical and role functioning of CTCL patients were better than other patients with cancer (p < 0.05) but worse than healthy population (p < 0.05). The social functioning was similar to other patients with cancer but worse than healthy (p < 0.05). In the global health status, better scores were observed with aging (p = 0.023) and worse scores in patients with Eastern Cooperative Oncology Group (ECOG)‐1 versus ECOG‐0 (p = 0.01). The Skindex‐29 global score was 28.5 (95% CI: 24.8–32.3), being worst at higher clinical stage (p < 0.05) and at higher pruritus intensity (p < 0.001) and better for older patients (p < 0.001). More itching was related to female sex (p = 0.016), younger patients (p = 0.035), higher ECOG (p < 0.05) and higher m‐SWAT scores (p = 0.006).Conclusions: These results allow mapping HRQoL affectation in CTCL patients. Global health status in MF/SS was like other patients with cancer and worse than the age‐matched healthy population. The highest impact in Skindex‐29 and EORTC‐QLQ‐C30 was associated with young age, ECOG, pruritus and disease stage.
- 8 May 2021
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 62 (9) , 2130-2140
Subcutaneous panniculitis-like T-cell lymphoma, lupus erythematosus profundus, and overlapping cases: molecular characterization through the study of 208 genes
Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) is a rare cytotoxic cutaneous lymphoma. Differential diagnosis with lupus erythematosus panniculitis (LEP) can be challenging and overlapping cases have been described. In this study, we investigate whether gene expression profiling may or not identify markers that can be used to improve our understanding of the disease and to make a precise differential diagnosis. SPTCL, LEP, and overlapping cases were analyzed using a customized NanoString platform including 208 genes related to T-cell differentiation, stromal signatures, oncogenes, and tumor suppressor genes. Gene expression unsupervised analysis of the samples differentiated SPTCL from LEP samples. Most overlapping cases were clustered with LEP cases. Differentially expressed genes were observed when comparing SPTCL with LEP cases; and overlapping with LEP cases. Gene set enrichment analysis recognized gene sets defining each group. In conclusion, SPTCL and LEP have distinctive molecular profiles and the molecular background of overlapping cases more closely resembles LEP.
- 8 May 2021
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 62 (9) , 2130-2140
Subcutaneous panniculitis-like T-cell lymphoma, lupus erythematosus profundus, and overlapping cases: molecular characterization through the study of 208 genes
Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) is a rare cytotoxic cutaneous lymphoma. Differential diagnosis with lupus erythematosus panniculitis (LEP) can be challenging and overlapping cases have been described. In this study, we investigate whether gene expression profiling may or not identify markers that can be used to improve our understanding of the disease and to make a precise differential diagnosis. SPTCL, LEP, and overlapping cases were analyzed using a customized NanoString platform including 208 genes related to T-cell differentiation, stromal signatures, oncogenes, and tumor suppressor genes. Gene expression unsupervised analysis of the samples differentiated SPTCL from LEP samples. Most overlapping cases were clustered with LEP cases. Differentially expressed genes were observed when comparing SPTCL with LEP cases; and overlapping with LEP cases. Gene set enrichment analysis recognized gene sets defining each group. In conclusion, SPTCL and LEP have distinctive molecular profiles and the molecular background of overlapping cases more closely resembles LEP.
- 8 February 2021
- Published by Wiley in International Journal of Dermatology
- Vol. 60 (9) , 1156-1158
Sonographic appearance of primary cutaneous B‐cell lymphomas
- 8 February 2021
- Published by Wiley in International Journal of Dermatology
- Vol. 60 (9) , 1156-1158
Sonographic appearance of primary cutaneous B‐cell lymphomas
- 2 December 2020
- Published by Wiley in Journal of Cutaneous Pathology
- Vol. 48 (5) , 650-658
Acral lymphomatoid papulosis: Report of five cases, differential diagnosis, and review
Acral lymphomatoid papulosis (a‐LyP) is a rare clinical variant of LyP whose diagnosis may be challenging. A case series of a‐LyP was studied clinically, histopathologically, immunohistochemically and from molecular point of view. Including ours, 25 cases of a‐LyP have so far been reported. Clinically, a‐LyP may present with exclusive acral involvement, associate mucosal lesions, which is a rare presentation by itself; or may be associated to conventional LyP. The age of presentation was slightly higher than that of conventional LyP (55 vs 45 years) and a male predominance has been observed, as usually reported. Histopathologically, no morphological differences with conventional LyP were observed. LyP type A and E where the main variants. We describe for the first time one case of type D a‐LyP. Acral LyP is a rare entity and correct diagnosis can only be reached with clinical and histopathological correlation, so as to avoid aggressive treatment of this indolent lymphoproliferative disorder.
- 2 December 2020
- Published by Wiley in Journal of Cutaneous Pathology
- Vol. 48 (5) , 650-658
Acral lymphomatoid papulosis: Report of five cases, differential diagnosis, and review
Acral lymphomatoid papulosis (a‐LyP) is a rare clinical variant of LyP whose diagnosis may be challenging. A case series of a‐LyP was studied clinically, histopathologically, immunohistochemically and from molecular point of view. Including ours, 25 cases of a‐LyP have so far been reported. Clinically, a‐LyP may present with exclusive acral involvement, associate mucosal lesions, which is a rare presentation by itself; or may be associated to conventional LyP. The age of presentation was slightly higher than that of conventional LyP (55 vs 45 years) and a male predominance has been observed, as usually reported. Histopathologically, no morphological differences with conventional LyP were observed. LyP type A and E where the main variants. We describe for the first time one case of type D a‐LyP. Acral LyP is a rare entity and correct diagnosis can only be reached with clinical and histopathological correlation, so as to avoid aggressive treatment of this indolent lymphoproliferative disorder.
- Open Access
- 24 June 2020
- Published by Wiley in British Journal of Haematology
- Vol. 190 (6) , e352-e356
Two independent consecutive lymphoma cases carry an identical MYD88 mutation but differ in their IGVH rearrangement
- 24 June 2020
- Published by Wiley in British Journal of Haematology
- Vol. 190 (6) , e352-e356
Open AccessTwo independent consecutive lymphoma cases carry an identical MYD88 mutation but differ in their IGVH rearrangement